Weight-Loss Injections and Cancer Risk: What Do the New Findings Show?
In this article
GLP-1 Injections: A Turning Point in Obesity Treatment
Today, obesityis more than a cosmetic issue: it is a major health crisis. According to the World Health Organization, worldwide, more than 650 million adults live with obesity. It creates conditions favoring chronic diseases ranging from type 2 diabetes and cardiovascular disease to hypertension, fatty liver disease, and certain cancers among many others.
In recent years, drugs commonly known as ‘weight-loss injections’— GLP-1 receptor agonists (GLP-1RAs) —have become a game-changing option. Initially developed for type 2 diabetes, they have moved beyond glucose control and transformed obesity treatment. Well-known examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
Clinical trials show remarkable weight-loss results:
- up to 15–20% weight loss within 12–18 months —difficult to achieve through conventional diet or exercise programs.
- Semaglutide trials found that 86% of participants lost at least 5% of body weight—a true revolution in obesity treatment.
- Tirzepatide took this further: the proportion losing weight exceeded 90% and average loss was approximately 22.5 kg in reports.
Beyond weight reduction, these effects improve glucose control, cardiovascular risk factors, and quality of life. In people receiving GLP-1RAs, investigators observed a 1–1.5% reduction in HbA1c and an average systolic blood pressure reduction of 5–6 mmHg with treatment.
Summary: GLP-1 receptor agonists are considered the first medications approaching bariatric surgery’s efficacy . Nevertheless, long-term safety questions—particularly cancer risk —remain critical unresolved issues.
A comprehensive study published on August 21, 2025 in JAMA Oncology addresses this question. It is among the first large analyses examining the association of long-term use of these transformative GLP-1RA obesity drugs with the risk of developing cancer specifically.
📊 New JAMA Oncology Study: GLP-1RAs and Cancer Risk
Hao Dai and colleagues (JAMA Oncology, August 2025) published a retrospective cohort study, among the largest to date evaluating long-term GLP-1 receptor agonist effects on cancer risk in this population.
🧪 Study Design
- Data source: OneFlorida+ health records (2014–2024).
- Participants: 86,632 adults with obesity (average age 52; 68% women).
- Comparison: 43,317 GLP-1RA users vs. 43,315 matched controls.
- Assessment: Incidence of 14 cancer types (13 obesity-related + lung cancer).
🔑 Findings
- Overall cancer risk decreased by 17%.
Incidence among GLP-1RA users: 13.6 /1000 person-years, versus nonusers: 16.4 /1000 person-years.
HR: 0.83 (95% CI 0.76–0.91; P=0.002) - Endometrial cancer risk decreased by 25% → HR: 0.75 (95% CI 0.57–0.99)
- Ovarian cancer risk decreased by 47% → HR: 0.53 (95% CI 0.29–0.96)
- Meningioma risk decreased by 31% → HR: 0.69 (95% CI 0.48–0.97)
- Kidney cancer risk increased by 38% (borderline significance) → HR: 1.38 (95% CI 0.99–1.93; P=0.04)
Study Message: GLP-1RA treatment significantly reduces overall cancer risk in people with obesity. Protection is particularly evident for endometrial cancer, ovarian cancer, and meningioma . However, caution is needed regarding kidney cancer risk and long-term monitoring is required.
🔙 Previous Findings: What Do We Know?
Potential cancer effects of GLP-1 receptor agonists have long attracted scientific attention. Trials, meta-analyses, and observational studies have offered clues:
- LEADER (liraglutide) and SUSTAIN (semaglutide) and other major diabetes trials initially raised concerns about pancreatic cancer risk . Long-term follow-up, however, showed no substantial increase in pancreatic cancer.
- A large 2023 meta-analysisfound that GLP-1RAs did not increase breast, colon, or pancreatic cancer risk . Based on millions of patient records, it offered reassurance.
- In 2024, The Lancet Diabetes & Endocrinologypublished a study suggesting GLP-1RAs could particularly reduce endometrial cancer risk . The new 2025 JAMA Oncology study strengthens these findings.
Summary: Earlier studies suggested GLP-1RAs do not increase cancer risk and may protect against certain tumors. The new JAMA data offer stronger support for this trend.
⚖️ GLP-1RAs or Bariatric Surgery?
GLP-1RA drugs and bariatric surgery are often compared for weight loss and cancer risk:
- Bariatric surgery (particularly gastric bypass), in long-term studies (10–20 years), reduces cancer incidence by 30–40%. It also produces diabetes remission and significant cardiovascular mortality reductions.
- GLP-1RA drugs show promising short-term results (15–20% weight loss, 17% lower cancer risk), but 10–20-year data are not yet available.
- Durability and mechanisms remain supported more strongly for surgery. However, medications offer an important advantage through their noninvasive nature.
- In the future, certain patient groups may receive drug + surgery combinations as personalized treatment strategies develop.
Note: GLP-1RAs are the first drugs approaching surgery-like weight loss. However, long-term durability remains unproven.
🧭 Clinical and Public Health Commentary
- Obesity is associated with 13 cancer types. GLP-1RAs producing weight loss and reducing certain cancer risks multiply their contribution to public health.
- The kidney cancer risk signal requires careful monitoring because effects may differ in some subgroups.
- Over the next 5–10 years, clearer evidence will establish whether GLP-1RAs are alternatives or complements to surgery . These clearer findings will also have a direct impact on health policy decisions.
✅ Conclusion: GLP-1RA treatment in obesity provides not only weight loss but also risk reduction for certain cancers. These data show that a ‘drug-based revolution’ against obesity is now real.
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.